녹내장에서 브리모니딘/티몰롤 복합제제와 0.15% 브리모니딘 사용 시 알레르기 발생률의 비교

• 영문명: Comparison of Allergy Prevalence between Brimonidine/Timolol Fixed Combination and 0.15% Brimonidine in Glaucoma Pati
• 발행기관: 대한안과학회
• 저자명: 박은정(Eun Jung Park) 전연숙(Yeoun Sook Chun)
• 간행물 정보: 『대한안과학회지』Ophthalmological Society,volume59,number5, 1~8쪽, 전체 8쪽
• 주제분류: 인문학 > 역사학
• 파일형태: PDF
• 발행일자: 2018.04.30

영문 초록

Purpose: To compare the allergy prevalence and clinical manifestations of 0.2% brimonidine/0.5% timolol fixed combination (BTFC) and 0.15% brimonidine in Korean patients with glaucoma. Methods: We retrospectively analyzed the medical records of 196 glaucoma patients treated with BTFC and 234 glaucoma patients treated with 0.15% brimonidine. We compared sex, age, type of glaucoma, treatment period, allergy history, onset time of ocular allergy and clinical characteristics of allergy in the two groups. Results: Ocular allergy percentages 10.14% in the BTFC group and 22.02% in the 0.15% brimonidine group, and the risk of allergy was approximately 0.4 times lower in patients using BTFC (hazard ratio = 2.5, p = 0.009). The BTFC group developed ocular allergy at a mean of 20.5 months (range: 1.7–51.1 months), and the 0.15% brimonidine group developed ocular allergy at a mean of 7.7 months (range: 0.4–50.8 months). In the BTFC group, 50% of the ocular allergy occurred within 15 months, and within 5 months in the 0.15% brimonidine group. Clinical characteristics of brimonidine allergy involved two types of conjunctival follicles and conjunctival papillae, but there were no significant differences in incidence according to allergy type (p = 0.566). Conclusions: The prevalence of ocular allergy in the BTFC group was lower than that in the 0.15% brimonidine group in Korean patients with glaucoma. The results of this study are expected to be useful for patient education and compliance improvement using brimonidine. J Korean Ophthalmol Soc 2018;59(5):451-458

목차

대상과 방법

고 찰

키워드

Glaucoma Korean Ocular allergy 0.2% brimonidine/0.5% timolol fixed combination 0.15% brimonidine